Sun Pharma Advanced Research Company
Sun Pharma Advanced Research Company Share Price Chart
Sun Pharma Advanced Research Company last traded at ₹184.16 (2026-10-13). Over the past month the stock moved -6.5%, three months the stock moved -21.6%, year the stock moved +28.5%. Its closing range over 52 weeks is ₹115.65 – ₹234.75, with the latest close 21.6% below the high.
Closing prices up to 2026-10-13.
About Sun Pharma Advanced Research Company
Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products.[1]
History[1] It is the first listed pharma R&D company out of India where founders still own 66% and continue to invest. SPARC was created through the demerger of Sun Pharmaceutical Industries Ltd.’s innovative R&D business but is not a Sun Pharma subsidiary.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Sun Pharma Advanced Research Company reported sales of ₹40.00 crore (+300.0%) and net profit of ₹-21.00 crore, compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 40.00 | -34.00 | -86.00 | -21.00 | -0.65 |
| Mar 2026 | 1,853 | 1,773 | 96.00 | 1,761 | 54.26 |
| Dec 2025 | 8.00 | -57.00 | -673.00 | -81.00 | -2.48 |
| Sep 2025 | 8.00 | -66.00 | -838.00 | -76.00 | -2.34 |
| Jun 2025 | 10.00 | -52.00 | -543.00 | -52.00 | -1.60 |
| Mar 2025 | 27.00 | -54.00 | -198.00 | -61.00 | -1.88 |
| Dec 2024 | 15.00 | -74.00 | -499.00 | -80.00 | -2.46 |
| Sep 2024 | 13.00 | -104.00 | -808.00 | -108.00 | -3.32 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -38.1% | +7.1% | +58.8% | -41.2% | -38.5% | -46.7% | +6763.0% | +300.0% |
| Operating profit growth | – | – | – | – | – | – | – | – |
| Net profit growth | – | – | – | – | – | – | – | – |
| EPS growth | – | – | – | – | – | – | – | – |
| OPM % | -808.0% | -499.0% | -198.0% | -543.0% | -838.0% | -673.0% | 96.0% | -86.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Sun Pharma Advanced Research Company reported sales of ₹1,879.00 crore (+2509.7%) and net profit of ₹1,552.00 crore, compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 1,879 | 1,598 | 85.00 | 1,552 | 47.83 |
| Mar 2025 | 72.00 | -327.00 | -456.00 | -345.00 | -10.64 |
| Mar 2024 | 76.00 | -404.00 | -534.00 | -388.00 | -11.96 |
| Mar 2023 | 239.00 | -214.00 | -90.00 | -223.00 | -6.86 |
| Mar 2022 | 137.00 | -187.00 | -136.00 | -203.00 | -7.48 |
| Mar 2021 | 253.00 | -135.00 | -53.00 | -151.00 | -5.77 |
| Mar 2020 | 77.00 | -310.00 | -404.00 | -312.00 | -11.92 |
| Mar 2019 | 183.00 | -151.00 | -83.00 | -145.00 | -5.55 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +134.6% | -57.9% | +228.6% | -45.8% | +74.5% | -68.2% | -5.3% | +2509.7% |
| Operating profit growth | – | – | – | – | – | – | – | – |
| Net profit growth | – | – | – | – | – | – | – | – |
| EPS growth | – | – | – | – | – | – | – | – |
| OPM % | -83.0% | -404.0% | -53.0% | -136.0% | -90.0% | -534.0% | -456.0% | 85.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Sun Pharma Advanced Research Company.
Get Free AI Stock Analysis FREE →Latest News
-
Aster DM, SPARC among 3 stocks looking strong on tech charts, says Geojit - Business Standard
-
Sparc Electrex shareholders approve three independent directors via postal ballot - scanx.trade
-
Sparc Electrex reports standalone net loss of Rs 0.05 crore in the June 2026 quarter - Business Standard
-
Sparc Electrex reports standalone net loss of Rs 0.05 crore in the June 2026 quarter - Business Standard
-
Sparc Electrex reports standalone net loss of Rs 0.05 crore in the June 2026 quarter - Business Standard
-
Ashish Chugh pares stake in Sparc Electrex, promoter sells 1.6% shares in Accent Microcell - Moneycontrol.com
-
When is the next results date for Sparc Electrex Ltd?
-
SPARC sells of priority review voucher in US for $195 million - Moneycontrol.com
-
SPARC surges after inking pact to sell Priority Review Voucher for $195 million
-
Sun Pharma Advanced Research Company Ltd. - Moneycontrol.com
Frequently Asked Questions
What is Sun Pharma Advanced Research Company's current stock price?
Sun Pharma Advanced Research Company shares were last quoted at ₹184.16 (-0.8% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Sun Pharma Advanced Research Company?
Sun Pharma Advanced Research Company has a price-to-earnings (P/E) ratio of 4.29 and a price-to-book (P/B) ratio of 5.16. The industry P/E is 5.78.
What is the 52-week high and low of Sun Pharma Advanced Research Company?
The 52-week high of Sun Pharma Advanced Research Company is ₹289.00 and the 52-week low is ₹108.20.
What is the market cap of Sun Pharma Advanced Research Company?
The market capitalisation of Sun Pharma Advanced Research Company is about ₹6,788.99 crore.
How did Sun Pharma Advanced Research Company perform in its latest quarterly results?
In the latest quarter (Jun 2026), Sun Pharma Advanced Research Company reported sales of ₹40.00 crore (+300.0%) and net profit of ₹-21.00 crore, compared with the same quarter last year.
Is Sun Pharma Advanced Research Company a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Sun Pharma Advanced Research Company has 3-year profit growth of 108.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Sun Pharma Advanced Research Company?
Promoters hold about 65.67% of Sun Pharma Advanced Research Company.
Which sector does Sun Pharma Advanced Research Company belong to?
Sun Pharma Advanced Research Company belongs to the Biotechnology & Medical Research sector.
Other Biotechnology & Medical Research stocks
- Biocon
- Concord Biotech
- Windlas Biotech
- Arvee Laboratories
- Softrak Venture Investment
- ANG Lifesciences India
- Vivo Biotech
- Genomic Valley Biotech
All Biotechnology & Medical Research stocks · Browse all stocks A–Z